Provided by Tiger Trade Technology Pte. Ltd.

Terns Pharmaceuticals, Inc.

52.95
0.0000
Volume:- -
Turnover:- -
Market Cap:6.11B
PE:-51.32
High:52.95
Open:52.95
Low:52.95
Close:52.95
52wk High:53.19
52wk Low:2.66
Shares:115.41M
Float Shares:113.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0319
EPS(LYR):-1.0326
ROE:-14.23%
ROA:-9.91%
PB:6.07
PE(LYR):-51.28

Loading ...

Company Profile

Company Name:
Terns Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.